Schossleitner Klaudia, Habertheuer Andreas, Finsterwalder Richard, Friedl Heinz P, Rauscher Sabine, Gröger Marion, Kocher Alfred, Wagner Christine, Wagner Stephan N, Fischer Gottfried, Schultz Marcus J, Wiedemann Dominik, Petzelbauer Peter
Department of Dermatology, Skin and Endothelium Research Division (SERD) Medical University of Vienna, Vienna, Austria.
Department of Cardiac Surgery Medical University of Vienna, Vienna, Austria.
PLoS One. 2015 Nov 4;10(11):e0142115. doi: 10.1371/journal.pone.0142115. eCollection 2015.
Despite significant advances in organ preservation, surgical techniques and perioperative care, primary graft dysfunction is a serious medical problem in transplantation medicine in general and a specific problem in patients undergoing lung transplantation. As a result, patients develop lung edema, causing reduced tissue oxygenation capacity, reduced lung compliance and increased requirements for mechanical ventilatory support. Yet, there is no effective strategy available to protect the grafted organ from stress reactions induced by ischemia/reperfusion and by the surgical procedure itself.
We assessed the effect of a cingulin-derived peptide, XIB13 or a random peptide in an established rat model of allogeneic lung transplantation. Donor lungs and recipients received therapeutic peptide at the time of transplantation and outcome was analyzed 100min and 28 days post grafting.
XIB13 improved blood oxygenation and reduced vascular leak 100min post grafting. Even after 28 days, lung edema was significantly reduced by XIB13 and lungs had reduced fibrotic or necrotic zones. Moreover, the induction of an allogeneic T cell response was delayed indicating a reduced antigen exchange between the donor and the host.
In summary, we provide a new tool to strengthen endothelial barrier function thereby improving outcomes in lung transplantation.
尽管在器官保存、手术技术和围手术期护理方面取得了重大进展,但原发性移植功能障碍在一般移植医学中是一个严重的医学问题,在肺移植患者中更是一个特殊问题。结果,患者会出现肺水肿,导致组织氧合能力下降、肺顺应性降低以及对机械通气支持的需求增加。然而,目前尚无有效的策略来保护移植器官免受缺血/再灌注及手术本身所引发的应激反应的影响。
我们在已建立的大鼠同种异体肺移植模型中评估了一种cingulin衍生肽XIB13或一种随机肽的作用。供体肺和受体在移植时接受治疗性肽,并在移植后100分钟和28天分析结果。
XIB13在移植后100分钟改善了血液氧合并减少了血管渗漏。即使在28天后,XIB13也显著减轻了肺水肿,且肺的纤维化或坏死区域减少。此外,同种异体T细胞反应的诱导延迟,表明供体与宿主之间的抗原交换减少。
总之,我们提供了一种新工具来增强内皮屏障功能,从而改善肺移植的结果。